Year All202620252024202320222021202020192018201720162015201420132012201120102007 02.26.24 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , Feb. 26, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the following sessions at two upcoming Read More 02.20.24 Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024 WALTHAM, Mass. , Feb. 20, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and year-end 2023 financial results and provide a business Read More 02.01.24 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , Feb. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences: A Read More 01.02.24 Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference WALTHAM, Mass. , Jan. 2, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger , Chief Executive Officer of Syndax, will present at the 42nd Annual J.P. Read More 01.02.24 Syndax Highlights Recent Updates and Anticipated 2024 Milestones – BLA submitted for axatilimab in chronic graft-versus-host disease; Syndax exercised option to co-commercialize axatilimab in the U.S. with Incyte – – NDA submitted for revumenib in R/R KMT2Ar acute leukemia under U.S. FDA's RTOR program – – Completion of enrollment in AUGMENT-101 mNPM1 patient Read More 12.19.23 Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass. , Dec. 19, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More 12.14.23 Syndax Announces Pricing of $200 Million Public Offering of Common Stock WALTHAM, Mass. , Dec. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 10,810,810 Read More 12.14.23 Syndax Announces Proposed $150 Million Public Offering of Common Stock WALTHAM, Mass. , Dec. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other Read More 12.12.23 Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting – Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate consistent across adult and pediatric patients – – 63% overall response rate; responses observed across all major subgroups – – Median overall survival Read More 12.11.23 Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials - Data collectively highlight revumenib's combination potential with current standard of care agents and support advancement into pivotal combination trials in the frontline setting - - 100% CRc observed in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly Read More 12.10.23 Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease - Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment - Data are featured in the Plenary Scientific Session at the 65 th American Society of Hematology Annual Meeting Read More 12.04.23 Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting WALTHAM, Mass. , Dec. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, Read More
02.26.24 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , Feb. 26, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the following sessions at two upcoming Read More
02.20.24 Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024 WALTHAM, Mass. , Feb. 20, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and year-end 2023 financial results and provide a business Read More
02.01.24 Syndax Announces Participation at Two Upcoming Investor Conferences WALTHAM, Mass. , Feb. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences: A Read More
01.02.24 Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference WALTHAM, Mass. , Jan. 2, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger , Chief Executive Officer of Syndax, will present at the 42nd Annual J.P. Read More
01.02.24 Syndax Highlights Recent Updates and Anticipated 2024 Milestones – BLA submitted for axatilimab in chronic graft-versus-host disease; Syndax exercised option to co-commercialize axatilimab in the U.S. with Incyte – – NDA submitted for revumenib in R/R KMT2Ar acute leukemia under U.S. FDA's RTOR program – – Completion of enrollment in AUGMENT-101 mNPM1 patient Read More
12.19.23 Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass. , Dec. 19, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More
12.14.23 Syndax Announces Pricing of $200 Million Public Offering of Common Stock WALTHAM, Mass. , Dec. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 10,810,810 Read More
12.14.23 Syndax Announces Proposed $150 Million Public Offering of Common Stock WALTHAM, Mass. , Dec. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other Read More
12.12.23 Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting – Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate consistent across adult and pediatric patients – – 63% overall response rate; responses observed across all major subgroups – – Median overall survival Read More
12.11.23 Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials - Data collectively highlight revumenib's combination potential with current standard of care agents and support advancement into pivotal combination trials in the frontline setting - - 100% CRc observed in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly Read More
12.10.23 Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease - Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment - Data are featured in the Plenary Scientific Session at the 65 th American Society of Hematology Annual Meeting Read More
12.04.23 Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting WALTHAM, Mass. , Dec. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, Read More